CANTAS Stock Overview
A biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cantargia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.17 |
| 52 Week High | SEK 8.57 |
| 52 Week Low | SEK 3.12 |
| Beta | 1.66 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 10.77% |
| 3 Year Change | -93.92% |
| 5 Year Change | n/a |
| Change since IPO | -72.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| CANTAS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | 0.3% |
| 1Y | 10.8% | -13.2% | 0.1% |
Return vs Industry: CANTAS exceeded the UK Biotechs industry which returned -28.7% over the past year.
Return vs Market: CANTAS exceeded the UK Market which returned -2.4% over the past year.
Price Volatility
| CANTAS volatility | |
|---|---|
| CANTAS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: CANTAS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CANTAS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 23 | Goran Forsberg | cantargia.com |
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04 (Nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer and non-small cell lung cancer, as well as Phase Ib/II for the treatment of triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It is also developing CANxx, an IL1RAP-based antibody platform.
Cantargia AB (publ) Fundamentals Summary
| CANTAS fundamental statistics | |
|---|---|
| Market cap | SEK 702.79m |
| Earnings (TTM) | -SEK 299.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.3x
P/E RatioIs CANTAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CANTAS income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 299.38m |
| Earnings | -SEK 299.37m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 22, 2024
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CANTAS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/21 04:56 |
| End of Day Share Price | 2023/08/24 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cantargia AB (publ) is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arvid Necander | Carnegie Investment Bank AB |
| Soo Romanoff | Edison Investment Research |
| null null | Life Sciences Research International BV |